RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.
Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs are first-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2)
Security Infrastructure as a Service (SIaaS). LimaCharlie abstracts away the hard parts of information security and delivers them on-demand (or à la carte) at scale in a manner similar to any major cloud provider drastically reducing costs and effort. We supply all the tools to run an MSSP or SOC as well as providing API’s that allow users to build and monetize their own products.
RedBud Brands is a brand development studio bringing people, ideas, and capital together to create disruptive new companies with an emphasis on the consumer space. It is an innovative venture platform for launching impactful brands that partners with visionary founders and executives to support and supercharge the creation of transformative, valuable, and sustainable companies. The company focuses primarily on premium, consumer packaged goods sectors with an emphasis on 'better-for-you' products.
Credo AI is on a mission to empower enterprises to responsibly build, adopt, procure and use AI at scale. Credo AI’s cutting-edge AI governance platform automates AI oversight and risk management, while enabling regulatory compliance to emerging global standards like the EU AI Act, NIST, and ISO. Credo AI keeps humans in control of AI, for better business and society. Founded in 2020, Credo AI has been recognized as a CBInsights AI 100, Technology Pioneer by the World Economic Forum, Fast Company’s Next Big Thing in Tech, and a top Intelligent App 40 by Madrona, Goldman Sachs, Microsoft and Pitchbook. To learn more, visit: credo.ai.
Speech Graphics delivers pioneering facial animation technology to the entertainment industry, working with clients such as Warner Brothers and Def Jam Recordings. Based on over 20 years of R&D in speech technology and procedural facial dynamics, our software produces high-quality facial animation from audio alone, with no need for motion capture. Speech Graphics spun out of the University of Edinburgh’s world-renowned School of Informatics in 2010 under the leadership of founders Michael Berger and Gregor Hofer, and game industry veteran Colin Macdonald. Speech Graphics has won several awards for its speech-driven animation technology, including the prestigious John Logie Baird Award for innovation, an LT-Innovate Award, a Santander Entrepreneurial Award, and game industry awards including a 2015 Develop Award for Best Creative Outsourcer and 2015 TIGA Award for Best Animation Supplier. The company has also received several development grants, including grants from Scottish Enterprise and the University of Abertay.
The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.
At Codoxo, formerly Fraudscope, we’re on a mission to make our healthcare system more affordable and effective. Our Forensic AI Platform uses a patented algorithm to identify problems and suspicious behavior earlier than traditional techniques which helps ensure our scarce healthcare dollars go to real patient care.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.
Upgrade is a neobank that offers credit to mainstream consumers through cards and personal loans, together with free credit monitoring and education tools that help consumers understand and manage their finances. Upgrade Card provides an innovative credit card that brings the low cost and responsible credit of installment lending to millions of retail locations in the U.S., while Upgrade Account is a mobile banking product offered to mainstream consumers.
Ankyra is a biotech company developing anchored immunotherapy for cancer treatments. Systemic dosing of these potent immune stimulants is restricted due to widespread immune activation and toxicity. When cytokines are injected into tumor tissue, they localize specifically and persistently, causing intense hot spots of inflammation that activate an anti-tumor immune response. Ankyra used its Anchored Immunotherapy Platform to develop ANK-101, a stable complex of a modified IL-12 cytokine with aluminum hydroxide (Alhydrogel) to overcome the limitations of traditional cytokine therapeutics. Alhydrogel, an FDA-approved adjuvant for use in human and veterinary vaccines, acts as a scaffold to locally retain the potent activity of IL-12 after intratumoral administration, improving its therapeutic window. Ankyra's mission is to optimize the impact of anchored immunotherapy to improve the lives of patients with cancer.
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success. They specifically apply its approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single-gene driver mutations or synthetic lethal contexts. The company aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials.
SafeBreach is a pioneer in the emerging category of breach and attack simulation. The company's groundbreaking platform provides a “hacker's view” of an enterprise’s security posture to proactively predict attacks, validate security controls and improve SOC analyst response. SafeBreach automatically executes breach methods with an extensive and growing Hacker’s Playbook of research and real-world investigative data. SafeBreach is funded by Sequoia Capital, Deutsche Telekom Capital, Hewlett Packard Pathfinder and investor Shlomo Kramer.
Mekonos creates a proprietary cell-engineering platform designed for cell therapies on a chip. Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development.
SafeRide Health is a healthcare technology platform developer that aims to simplify medical transportation, expedite care coordination, and improve patient outcomes. The company's platform enables health plans to manage its members with greater intelligence and control, delivering end-to-end data transparency while improving patient experience, population health, and programs, and giving patented fleet management solutions to the healthcare industry.
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.
Bridgit is workforce intelligence for the construction industry. Bridgit’s mission is simple — to help the construction industry maximize profits by taking a people-first approach. Workforce Intelligence from Bridgit transforms workforce data into actionable insights that inform an organization's strategic and tactical business decisions. Bridgit works with construction industry leaders like Skanska, Balfour Beatty, and Ryan Companies, among others. Bridgit is a privately held company, having raised over $35 million USD in equity financing, with capital from investors such as Autodesk, BDC Capital’s Women in Technology Venture Fund, Camber Creek, Export Development Canada, IAF, Nine Four Ventures, Salesforce Ventures, Sands Capital, StandUp Ventures, Storm Ventures, and Vanedge Capital.
WASHINGTON, D.C. March 05, 2020 – HUNGRY Marketplace Inc., the Washington D.C. based platform connecting top chefs with businesses looking for the best in catered meals, today announced the close of its nearly $20 million Series B funding round. The round was led by former Whole Foods co-CEO Walter Robb and Evolution VC Partners. Additional participants in the round included actor Kevin Hart, Jay-Z’s Marcy Venture Partners, Los Angeles Ram Todd Gurley, Seattle Seahawk Bobby Wagner, Tampa Bay Buccaneer Ndamukong Suh, former White House chef Sam Kass, President Obama’s special assistant Reggie Love and Leonard Green Partners’ Jonathan Sokoloff. The investment brings the company’s total funding to $32.5 million. ABOUT HUNGRY: HUNGRY was founded by serial entrepreneurs Eman Pahlavani, Shy Pahlevani and Jeff Grass, as a revolutionary way for independent chefs to connect with the $60 billion business and events catering market. HUNGRY is committed to improving the communities it serves. Through its ‘Fight Against Hunger’ program, HUNGRY donates one meal to those in need for every two purchased. Additionally, its ‘WeRecycle’ program promotes environmental waste reduction by offering biodegradable plates and cutlery with its delivered meals. HUNGRY is headquartered in Washington, D.C. and has rapidly growing operations in Philadelphia, Atlanta, Boston and New York City. By the end of 2021, HUNGRY is projected to expand its footprint to a total of 23 U.S. cities. For more information, visit tryhungry.com.
Disruption in healthcare is accelerated by the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions. With the mission to tackle the massive oncology dilemma, Elephas is leading the way to change how clinicians treat cancer patients. By harnessing the latest advances in cancer biology, multimodal microscopy, and artificial intelligence, the Elephas platform has the ability to empower clinical decision-making and accelerate drug development.
JumpCloud is an open directory platform for secure, frictionless access from any device to any resource, anywhere. JumpCloud’s mission is to Make Work Happen, providing simple, secure access to corporate technology resources from any device, or any location. The JumpCloud Directory Platform gives IT, security operations, and DevOps a single, cloud-based solution to control and manage employee identities, their devices, and apply Zero Trust principles. JumpCloud has a global user base of more than 100,000 organizations, with over 3,000 customers including Cars.com, GoFundMe, Grab, ClassPass, Uplight, Beyond Finance, and Foursquare. JumpCloud is backed by BlackRock, General Atlantic, OpenView, and Foundry Group.
Snyk empowers the world’s developers to build secure applications and equip security teams to meet the demands of the digital world. Its developer-first approach ensures organizations can secure all of the critical components of their applications from code to cloud, increase developer productivity, revenue growth, customer satisfaction, cost savings, and an overall improved security posture. Snyk’s Developer Security Platform automatically integrates with a developer’s workflow and is purpose-built for security teams to collaborate with their development teams. Snyk is used by 1,200 customers worldwide today, including industry leaders such as Asurion, Google, Intuit, MongoDB, New Relic, Revolut, and Salesforce. Snyk is recognized on the Forbes Cloud 100 2021.
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.
PolyAI develops a machine learning platform for conversational artificial intelligence. PolyAI builds enterprise voice assistants that carry on natural conversations with customers to solve their problems. PolyAI's voice assistants understand customers, regardless of what they say or how they say it. Founded in 2017, the company has its headquarters in London, England, United Kingdom, and New York, United States of America.
#Paid is a tech company that operates a creative marketing platform that combines brand and creator collaboration. The platform allows brands to collaborate with relevant artists, travelers, storytellers, and photographers from all over the world for product placement on social media platforms.
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Gusto is a company that provides a cloud-based platform designed for small and medium-sized businesses to manage payroll, benefits, and human resources. Founded in 2011 and headquartered in San Francisco, with an additional office in Denver, Gusto offers an array of services including payroll processing, health benefits, workers' compensation, and time tracking. The platform allows employers and employees to access payroll information from various devices, enabling features such as browsing pay stubs, reviewing tax forms, and verifying personal details. Gusto caters to a diverse clientele, including startups, coffee shops, medical practices, creative agencies, and law firms, aiming to simplify the administrative tasks associated with employee management.
Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.
Keeping technology at the core, Blackbuck is redefining the logistics landscape of India, making it reliable and efficient. Blackbuck's comprehensive approach to problems creates impact on the entire ecosystem of transportation, which stitches across large number of livelihoods. The transportation sector is ripe for a revolution, and Blackbuck marks the beginning. Founded in 2015, BlackBuck has been a pioneer in bringing the offline operations of trucking online, be it matching a shipper with a trucker or reshaping the infrastructure around trucking to facilitate payments, insurance, and financial services. BlackBuck is committed to making it easier for millions of truckers to book a load and move at capacity and enable shippers of all sizes to have access to the right truck, at the right time for the right price – all at a click of a button. Today, BlackBuck is India’s largest trucking network, and the company’s robust technology platforms deliver reliability, efficiency and seamless experience for shippers and truckers. BlackBuck is powered by a 2000 strong incredible team and is supported by the best of investors’ fraternity that includes Accel Partners, Apoletto Asia, B Capital, Flipkart, Goldman Sachs, IFC, Light Street, Sands Capital, Sequoia Capital, Tiger Global and Wellington. BlackBuck has won ‘CNBC-TV18 - Young Turks Startup of the Year’ award and ‘Zee Business- Company of the year-Logistics’ award in 2018. BlackBuck is also the subject of a ‘Harvard Business School’ case study.
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.
Primer is an internet company that helps companies understand massive stores of text data using AI. It uses machine learning techniques to help parse and collate a large number of documents across several languages in order to facilitate further investigation.
Nubank is a prominent digital bank revolutionizing finance with its customer-centric approach. It provides a variety of services, including credit cards, personal loans, and digital payments, all accessible through a simple mobile app. Known for transparency, ease of use, and low fees, Nubank aims to empower users with innovative solutions for better financial management.
Outreach is a sales engagement platform that accelerates revenue growth by optimizing every interaction throughout the customer lifecycle. The platform manages all customer interactions across email, voice and social, and leverages machine learning to guide reps to take the right actions. Thousands of customers, including Cloudera, Glassdoor, Pandora, and Zillow, rely on Outreach to drive predictable and measurable growth, increase efficiency and effectiveness of customer-facing teams, and improve visibility into sales activity and performance.
Klaviyo is a marketing automation and email platform designed to help grow businesses. From personalized newsletters to automated emails like abandoned carts, order follow-ups, and personalized thank you's, Klaviyo makes it easy for stores to set up email marketing without the need for expensive systems and lots of people. It integrates natively with customer data sources and builds the technology to house data at scale, creates experiences across channels, and measures the results.
Lyra helps companies improve access to effective, high-quality mental health care for their employees. Lyra's matching technology and innovative digital platform connect members to a curated network of top therapists and coaches, which results in 3x more people receiving care and 7x better outcomes than traditional plans and EAPs. Members can find the right personalized care, match with the right provider for their needs, and feel motivated and supported throughout the entire treatment journey.
Boom Entertainment is a technology company developing a sports gaming application focusing on casual games for the sports betting industry. The company works with professional sports leagues, media companies, and casino operators.
Tellius is an AI-powered business analytics platform designed to help enterprises accelerate data-driven insight and decision-making. Tellius extends traditional self-service BI concepts through the use of search-enabled visualizations and a proprietary recommendation engine that automates the basic interpretation and analysis of data. Using machine learning, Tellius analyzes data to find hidden correlations, trends, and anomalies which are then presented as a set of suggested visualizations and predictive models. Unlike traditional BI tools, Tellius is built on a distributed architecture (Apache Spark) which provides the scale and performance required for Big Data environments.
Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Snyk empowers the world’s developers to build secure applications and equip security teams to meet the demands of the digital world. Its developer-first approach ensures organizations can secure all of the critical components of their applications from code to cloud, increase developer productivity, revenue growth, customer satisfaction, cost savings, and an overall improved security posture. Snyk’s Developer Security Platform automatically integrates with a developer’s workflow and is purpose-built for security teams to collaborate with their development teams. Snyk is used by 1,200 customers worldwide today, including industry leaders such as Asurion, Google, Intuit, MongoDB, New Relic, Revolut, and Salesforce. Snyk is recognized on the Forbes Cloud 100 2021.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
WireWheel.io is a software company that revolutionizes data privacy and protection as-a-service for companies. WireWheel delivers a cloud-based solution to to help global organizations become GDPR-ready and operationalize privacy in the enterprise.
Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.
Coagulo is transforming medicine with the first portable and connected precision-medicine platform for smarter management of coagulation, enabling better healthcare outcomes for everyone.
StockX operates a live bid/ask marketplace for buying and selling limited edition and high demand sneakers. Its marketplace enables users to anonymously buy and sell limited edition consumer products with stock market-like visibility. StockX’s platform allows users to create their own personalized sneaker portfolio by uploading their current collection and compare and contrast their sneaker collection to other users on the platform. The company was founded in March 2015, with its headquarters in Detroit in Michigan.
Uhnder is a start-up developing products for sensing, cognition, and communication for the Internet of Things (IoT) market. It is headquartered in California with engineering and operations based in Austin and St. Louis. Uhnder develops a digital automotive radar-on-chip designed to automate systems for safety and better feedback response. Uhnder disrupts the autonomous vehicle business with what it says is a more accurate and reliable alternative to light detection and ranging, known as lidar, which is one of the most common technologies used to make vehicles more aware of their surroundings. Uhnder's chip helps to avoid collisions, alerts to potential problems, helps with quick localization, as electronic fences for navigation and localization and for communication.
Papercup automates large parts of the dubbing process so content owners can localize their videos at scale, faster and at a fraction of the price of traditional methods. Our AI voices are indistinguishable from human's and our human-in-the-loop system means professional translators quality check all voiceovers for utmost accuracy.
Brightflag enables organizations to take control of their legal spend with AI-powered software that’s easy to use and backed by proactive customer support. Brightflag processes billions of dollars of legal spend annually on behalf of its customers, resulting in hundreds of millions of dollars in savings and tens of thousands of hours in avoided administrative work. Founded in 2014, Brightflag serves a global community of in-house legal teams and their vendors from its offices in Dublin, New York, and Sydney.
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
Scopely is an interactive entertainment and video game company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Stumble Guys”, and “Yahtzee With Buddies,” among others. Scopely creates, publishes, and live-operates immersive games that empower a directed-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami™ that supports one of the diversified portfolios in the mobile games industry. Recognized multiple times as Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has operations in more than a dozen markets across Asia-Pacific, including Bangalore and Shanghai, among others; EMEA, including Barcelona and Dublin, among others; and North America, including Boulder, Colorado, and Culver City, California, among others, with additional game studio partners across four continents.
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts.
Private Equity Round in 2020
BYJU’S is a global ed-tech company that provides highly adaptive, engaging, and effective learning solutions to more than 150 million students around the world. Founded in India in 2011, BYJU's mission is to make high-quality learning accessible to students everywhere. The BYJU's family of brands includes Disney-BYJU's Early Learn, BYJU's FutureSchool, Epic!, Osmo, Tynker, Toppr, and WhiteHat Jr., along with the company’s beloved flagship product, BYJU's: The Learning App. Together, BYJU's solutions support pre-K–12 education and a wide range of competitive exams. BYJU’S delivers a world-class learning experience with tools that sit at the crossroads of mobile, interactive content, and personalized learning methodologies. Byju's geography-agnostic solutions and 12,000+ teachers make learning engaging with visual and contextual programs that adapt to the unique learning style, skill level, and pace of each student. In addition, BYJU’S has innovative partnerships with some of the world's largest companies, including Disney and Google, to drive engagement and help even more students become active and lifelong learners. BYJU’S is backed by blue-chip investors including the Chan-Zuckerberg Initiative, Sequoia Capital, Bond Capital, Silver Lake, BlackRock, Sands Capital Management, Alkeon Capital Management, Sofina, Verlinvest, Tencent, Prosus (previously Naspers Ventures), CPPIB, General Atlantic, Tiger Global, Qatar Investment Authority, Owl Ventures, Lightspeed Venture Partners, Times Internet, Aarin Capital, and IFC. Since 2017, BYJU’S has completed more than 15 acquisitions, including companies in the U.S., UK, Austria, India, and Singapore. A 2021 Time 100 Most Influential Company, BYJU’S is headquartered in India, with operations in more than 21 countries globally and learning programs in more than 8 languages.
Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.
Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.
Bridgit is workforce intelligence for the construction industry. Bridgit’s mission is simple — to help the construction industry maximize profits by taking a people-first approach. Workforce Intelligence from Bridgit transforms workforce data into actionable insights that inform an organization's strategic and tactical business decisions. Bridgit works with construction industry leaders like Skanska, Balfour Beatty, and Ryan Companies, among others. Bridgit is a privately held company, having raised over $35 million USD in equity financing, with capital from investors such as Autodesk, BDC Capital’s Women in Technology Venture Fund, Camber Creek, Export Development Canada, IAF, Nine Four Ventures, Salesforce Ventures, Sands Capital, StandUp Ventures, Storm Ventures, and Vanedge Capital.
Outreach is a sales engagement platform that accelerates revenue growth by optimizing every interaction throughout the customer lifecycle. The platform manages all customer interactions across email, voice and social, and leverages machine learning to guide reps to take the right actions. Thousands of customers, including Cloudera, Glassdoor, Pandora, and Zillow, rely on Outreach to drive predictable and measurable growth, increase efficiency and effectiveness of customer-facing teams, and improve visibility into sales activity and performance.
Samsara is the pioneer of the Connected Operations™ Cloud, which is a platform that enables organizations that depend on physical operations to harness Internet of Things (IoT) data to develop actionable insights and improve their operations. With tens of thousands of customers across North America and Europe, Samsara is a proud technology partner to the people who keep our global economy running, including the world’s leading organizations across construction, transportation and warehousing, field services, manufacturing, retail, logistics, and public sector. The company’s mission is to increase the safety, efficiency, and sustainability of the operations that power the global economy.
Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system. The company is driven by a mission to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.
Private Equity Round in 2020
Globalization Partners’ Global Expansion Platform™ enables you to hire in more than 150 countries within days, and without the need to set up costly foreign subsidiaries. You identify great talent anywhere in the world, and we put them on our fully compliant global payroll - lifting the burden of global corporate tax, legal, and HR matters from your shoulders to ours. Whether it’s to test a new market or expand your talent pool, Globalization Partners is the most trustworthy solution in the market. We have dual U.S. headquarters to serve you in Boston and San Diego, and regional hub offices located worldwide in Germany, the UAE, India, Brazil, Mexico, Singapore, and the UK. Globalization Partners is also the only global employer of record that is Privacy Shield certified for HR Data. To find out more, please visit https://www.globalization-partners.com.
ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.
Scopely is an interactive entertainment and video game company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Stumble Guys”, and “Yahtzee With Buddies,” among others. Scopely creates, publishes, and live-operates immersive games that empower a directed-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami™ that supports one of the diversified portfolios in the mobile games industry. Recognized multiple times as Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has operations in more than a dozen markets across Asia-Pacific, including Bangalore and Shanghai, among others; EMEA, including Barcelona and Dublin, among others; and North America, including Boulder, Colorado, and Culver City, California, among others, with additional game studio partners across four continents.
DataRobot delivers AI technology and ROI enablement services to global enterprises. DataRobot’s enterprise AI platform democratizes data science with end-to-end automation for building, deploying, and managing machine learning models.
Doordash provides restaurant food delivery services connecting customers with local businesses. The company is passionate about transforming local businesses and is dedicated to enabling new ways of working, earning, and living. By building the last-mile delivery infrastructure for local cities Doordash is bringing communities closer. It connects customers with their favorite local and national restaurants and Fang, Evan Moore, Stanley Tang, and Tony Xu launched the company as PaloAltoDelivery.com in 2013, which became DoorDash, Inc. in October 2014.
Keeping technology at the core, Blackbuck is redefining the logistics landscape of India, making it reliable and efficient. Blackbuck's comprehensive approach to problems creates impact on the entire ecosystem of transportation, which stitches across large number of livelihoods. The transportation sector is ripe for a revolution, and Blackbuck marks the beginning. Founded in 2015, BlackBuck has been a pioneer in bringing the offline operations of trucking online, be it matching a shipper with a trucker or reshaping the infrastructure around trucking to facilitate payments, insurance, and financial services. BlackBuck is committed to making it easier for millions of truckers to book a load and move at capacity and enable shippers of all sizes to have access to the right truck, at the right time for the right price – all at a click of a button. Today, BlackBuck is India’s largest trucking network, and the company’s robust technology platforms deliver reliability, efficiency and seamless experience for shippers and truckers. BlackBuck is powered by a 2000 strong incredible team and is supported by the best of investors’ fraternity that includes Accel Partners, Apoletto Asia, B Capital, Flipkart, Goldman Sachs, IFC, Light Street, Sands Capital, Sequoia Capital, Tiger Global and Wellington. BlackBuck has won ‘CNBC-TV18 - Young Turks Startup of the Year’ award and ‘Zee Business- Company of the year-Logistics’ award in 2018. BlackBuck is also the subject of a ‘Harvard Business School’ case study.
UiPath develops and provides robotic process automation software designed to enhance operational efficiency across various industries. The company offers a comprehensive platform for hyper automation, enabling enterprises to discover, build, manage, and optimize automation opportunities. Key products include UiPath Studio, which allows users to design automation processes with an intuitive graphical interface, and UiPath Orchestrator, which manages automation workflows and deployments. UiPath’s solutions cater to a variety of sectors, including finance, healthcare, insurance, and telecommunications, facilitating the automation of tasks such as accounts payable, claims processing, and customer service. Founded in 2005 and headquartered in New York, UiPath also has offices in several major cities worldwide, including London, Bucharest, and Tokyo. The company focuses on integrating advanced technologies, such as artificial intelligence, to streamline processes and improve business outcomes.
908 Devices is bringing the powerful capabilities of Mass Spectrometry out of the confines of centralized facilities and mobile laboratories. The company makes battery-operated, handheld, chemical detection tools, rugged enough to exceed military standards, and trusted enough for immediate action in the field. For biologists and chemists in need of answers, 908 Devices makes personal analyzers, small and simple enough for every workspace.
Brightflag enables organizations to take control of their legal spend with AI-powered software that’s easy to use and backed by proactive customer support. Brightflag processes billions of dollars of legal spend annually on behalf of its customers, resulting in hundreds of millions of dollars in savings and tens of thousands of hours in avoided administrative work. Founded in 2014, Brightflag serves a global community of in-house legal teams and their vendors from its offices in Dublin, New York, and Sydney.
WASHINGTON, D.C. March 05, 2020 – HUNGRY Marketplace Inc., the Washington D.C. based platform connecting top chefs with businesses looking for the best in catered meals, today announced the close of its nearly $20 million Series B funding round. The round was led by former Whole Foods co-CEO Walter Robb and Evolution VC Partners. Additional participants in the round included actor Kevin Hart, Jay-Z’s Marcy Venture Partners, Los Angeles Ram Todd Gurley, Seattle Seahawk Bobby Wagner, Tampa Bay Buccaneer Ndamukong Suh, former White House chef Sam Kass, President Obama’s special assistant Reggie Love and Leonard Green Partners’ Jonathan Sokoloff. The investment brings the company’s total funding to $32.5 million. ABOUT HUNGRY: HUNGRY was founded by serial entrepreneurs Eman Pahlavani, Shy Pahlevani and Jeff Grass, as a revolutionary way for independent chefs to connect with the $60 billion business and events catering market. HUNGRY is committed to improving the communities it serves. Through its ‘Fight Against Hunger’ program, HUNGRY donates one meal to those in need for every two purchased. Additionally, its ‘WeRecycle’ program promotes environmental waste reduction by offering biodegradable plates and cutlery with its delivered meals. HUNGRY is headquartered in Washington, D.C. and has rapidly growing operations in Philadelphia, Atlanta, Boston and New York City. By the end of 2021, HUNGRY is projected to expand its footprint to a total of 23 U.S. cities. For more information, visit tryhungry.com.
Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.
Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics is advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.
Bridgit is workforce intelligence for the construction industry. Bridgit’s mission is simple — to help the construction industry maximize profits by taking a people-first approach. Workforce Intelligence from Bridgit transforms workforce data into actionable insights that inform an organization's strategic and tactical business decisions. Bridgit works with construction industry leaders like Skanska, Balfour Beatty, and Ryan Companies, among others. Bridgit is a privately held company, having raised over $35 million USD in equity financing, with capital from investors such as Autodesk, BDC Capital’s Women in Technology Venture Fund, Camber Creek, Export Development Canada, IAF, Nine Four Ventures, Salesforce Ventures, Sands Capital, StandUp Ventures, Storm Ventures, and Vanedge Capital.
PolyAI develops a machine learning platform for conversational artificial intelligence. PolyAI builds enterprise voice assistants that carry on natural conversations with customers to solve their problems. PolyAI's voice assistants understand customers, regardless of what they say or how they say it. Founded in 2017, the company has its headquarters in London, England, United Kingdom, and New York, United States of America.
Teckro is a life science technology company that is rethinking every element of clinical research - the people, the processes, and the technologies used. By making it possible for all relevant information to be instantly accessible to every active member of a clinical trial and for the entire study teams to be connected effortlessly, Teckro is broadening the possibilities of what they can achieve. Teckro's solutions result in quicker development of drugs and treatments for the world’s most complex diseases. The company was founded in 2015 and is based in Limerick, Ireland with offices in Dublin and Nashville.
Health Catalyst is a tech platform that organizes and links health-related data from different systems. It helps organize, normalize, and link the data from all different systems and make it searchable by all users, even the non-technical.
Health Catalyst is a tech platform that organizes and links health-related data from different systems. It helps organize, normalize, and link the data from all different systems and make it searchable by all users, even the non-technical.
Allvision is a software company providing high definition, time-based maps for mobility, infrastructure, and transportation. The company's core product is a platform that aggregates multiple sources of 3D data and, through the power of Machine Learning and Cloud Computing, provides analysis to derive actionable information. It enables street-level analytics on a global scale, making sense of our dynamic environment to solve the world’s most pressing problems. Allvision's goal is to improve the world by connecting decision-makers with rich sources of spatial data and analytics. We take data meant for robots and use them to arms companies and institutions with insights and intelligence from the ever-changing world around them.
SeLux Diagnostics is a developer of the next-generation phenotyping platform that provides personalized antimicrobial therapies to patients. The company is revolutionizing patient care by expediting the selection of personalized antimicrobial therapy for all infectious disease patients. This advancement will save lives, reduce hospital stays, and address the escalating antibiotic resistance epidemic by minimizing the overuse of broad-spectrum agents.
WireWheel.io is a software company that revolutionizes data privacy and protection as-a-service for companies. WireWheel delivers a cloud-based solution to to help global organizations become GDPR-ready and operationalize privacy in the enterprise.
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
Keeping technology at the core, Blackbuck is redefining the logistics landscape of India, making it reliable and efficient. Blackbuck's comprehensive approach to problems creates impact on the entire ecosystem of transportation, which stitches across large number of livelihoods. The transportation sector is ripe for a revolution, and Blackbuck marks the beginning. Founded in 2015, BlackBuck has been a pioneer in bringing the offline operations of trucking online, be it matching a shipper with a trucker or reshaping the infrastructure around trucking to facilitate payments, insurance, and financial services. BlackBuck is committed to making it easier for millions of truckers to book a load and move at capacity and enable shippers of all sizes to have access to the right truck, at the right time for the right price – all at a click of a button. Today, BlackBuck is India’s largest trucking network, and the company’s robust technology platforms deliver reliability, efficiency and seamless experience for shippers and truckers. BlackBuck is powered by a 2000 strong incredible team and is supported by the best of investors’ fraternity that includes Accel Partners, Apoletto Asia, B Capital, Flipkart, Goldman Sachs, IFC, Light Street, Sands Capital, Sequoia Capital, Tiger Global and Wellington. BlackBuck has won ‘CNBC-TV18 - Young Turks Startup of the Year’ award and ‘Zee Business- Company of the year-Logistics’ award in 2018. BlackBuck is also the subject of a ‘Harvard Business School’ case study.
nanoView Diagnostics Inc. (dba NanoView Biosciences), is developing proprietary products that support research, translation and delivery of precision medicine. The Company was founded on a novel technology platform that uniquely identifies and characterizes exosomes. Our high-throughput, cost-effective analysis solutions enable life science researchers to better understand the biological role of exosomes and how to utilize them as biomarkers to provide improved insight for how diseases are diagnosed, treated and monitored.
Upgrade is a neobank that offers credit to mainstream consumers through cards and personal loans, together with free credit monitoring and education tools that help consumers understand and manage their finances. Upgrade Card provides an innovative credit card that brings the low cost and responsible credit of installment lending to millions of retail locations in the U.S., while Upgrade Account is a mobile banking product offered to mainstream consumers.
Slack Technologies, Inc. operates a business communication platform that enhances collaboration among teams by integrating messaging, voice and video calls, file sharing, and workflow automation. Founded in 2009 and headquartered in San Francisco, California, Slack serves a diverse clientele ranging from Fortune 100 companies to small businesses, aiming to streamline communication and improve productivity. The platform is delivered as a software-as-a-service solution, allowing users to connect with the right people and information efficiently. Additionally, Slack has established the Slack Fund, an investment initiative focused on early-stage ventures in the technology sector, further promoting innovation in workplace productivity tools.
Farcast is a clinical diagnostic company whose mission it is to illuminate personal treatment truth of a cancer patient. The Farcast technology core is a human tumor micro-environment that enables oncologists and drug developers to test individual tumors to determine treatment response profiles. The company has its headquarters in Boston in Massachusetts, and operates a lab in Bangalore in India.
Neptune Financial (NepFin) is a next-generation financial services company whose commercial lending platform provides growth capital to mid-sized American businesses. With its team's experience in technology, traditional leveraged finance, and online lending, the company is poised to transform the way that middle-market borrowers access debt financing. Based in San Francisco, NepFin is supported by the same early investors as SoFi, Funding Circle, Lending Club and Upgrade. For more information please visit www.nepfin.com.
BigBasket is an online food and grocery store that delivers personal and household needs right to customers' doorstep. The company believes in being smart, quick, and efficient making life as leisurely as possible. Customers can browse through the vast range of products at bigbasket.com, order, and get them to be delivered at the customers' own convenient time slot. The company handpicks each and every product, putting it through a safety packaging process, and delivering to customers' home.
Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.
BigBasket is an online food and grocery store that delivers personal and household needs right to customers' doorstep. The company believes in being smart, quick, and efficient making life as leisurely as possible. Customers can browse through the vast range of products at bigbasket.com, order, and get them to be delivered at the customers' own convenient time slot. The company handpicks each and every product, putting it through a safety packaging process, and delivering to customers' home.
BigBasket is an online food and grocery store that delivers personal and household needs right to customers' doorstep. The company believes in being smart, quick, and efficient making life as leisurely as possible. Customers can browse through the vast range of products at bigbasket.com, order, and get them to be delivered at the customers' own convenient time slot. The company handpicks each and every product, putting it through a safety packaging process, and delivering to customers' home.
Teckro is a life science technology company that is rethinking every element of clinical research - the people, the processes, and the technologies used. By making it possible for all relevant information to be instantly accessible to every active member of a clinical trial and for the entire study teams to be connected effortlessly, Teckro is broadening the possibilities of what they can achieve. Teckro's solutions result in quicker development of drugs and treatments for the world’s most complex diseases. The company was founded in 2015 and is based in Limerick, Ireland with offices in Dublin and Nashville.
The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.
Uhnder is a start-up developing products for sensing, cognition, and communication for the Internet of Things (IoT) market. It is headquartered in California with engineering and operations based in Austin and St. Louis. Uhnder develops a digital automotive radar-on-chip designed to automate systems for safety and better feedback response. Uhnder disrupts the autonomous vehicle business with what it says is a more accurate and reliable alternative to light detection and ranging, known as lidar, which is one of the most common technologies used to make vehicles more aware of their surroundings. Uhnder's chip helps to avoid collisions, alerts to potential problems, helps with quick localization, as electronic fences for navigation and localization and for communication.
Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions. The company was founded in 2012 and is based in Lebanon, New Hampshire.
Scopely is an interactive entertainment and video game company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Stumble Guys”, and “Yahtzee With Buddies,” among others. Scopely creates, publishes, and live-operates immersive games that empower a directed-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami™ that supports one of the diversified portfolios in the mobile games industry. Recognized multiple times as Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has operations in more than a dozen markets across Asia-Pacific, including Bangalore and Shanghai, among others; EMEA, including Barcelona and Dublin, among others; and North America, including Boulder, Colorado, and Culver City, California, among others, with additional game studio partners across four continents.